CPhI Worldwide: Saltigo Adds High-Potency Capability in the U.S., Boosts Prospects for Japanese Market

Saltigo, the custom manufacturing arm of Lanxess, says it will build new manufacturing facilities at Redmond, WA for manufacturing highly potent active pharma ingredients (HPAPI). The facility has been designed to meet the needs of the firm’s U.S. pharmaceutical customers. It is set to manufacture category III and category IV highly potent drugs up to the kilogram level from the beginning of 2012. Once the facility is operational Saltigo will be able to manufacture active ingredients with an occupational exposure limit (OEL) of less than 10 micrograms/cu m...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers